FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200375449> ?p ?o ?g. }

• W4200375449 abstract "KRAS is the most frequently mutated oncogene in human tumors and drives tumorigenesis across multiple lineages. Specifically, KRAS is mutated in about 30% of lung cancer and over 90% of pancreatic cancer. Despite recent progress in developing mutant selective KRAS^G12C inhibitors, patient treatment options for RAS activated cancers remain very limited. Targeting the MAPK pathway by means of MEK and ERK inhibitors has been explored as an alternative strategy for KRAS mutant cancer. However, the clinical benefit is modest due to drug resistance caused by reactivation of the MAPK pathway and potentially other pathways and/or bypass mechanisms. Here we used CRISPR-based screens to identify potential combination therapy targets to enhance trametinib response in KRAS mutant cancers. We screened in five KRAS mutant cell lines of lung and pancreatic lineages and identified both known as well as novel modulators of MEK inhibitor response. Consistent with previous reports, gene knockouts that impair the reactivation of ERK downstream of MEK inhibition scored as top hits in our drop-out screens. Knocking out MAPK1, RAF1, BRAF and PTPN11 sensitized all five cell lines to trametinib treatment supporting these as candidate drug combination targets for MAPK pathway inhibition. Our screens also identified multiple genes within the heparan sulfate pathway (EXT1, EXT2, EXTL3, XYLT2, ALG6, B3GAT3, B4GALT7 and HS2ST1) and the MAPK7 pathway (MAPK7 and MAP2K5) that sensitize multiple but not all cell lines to trametinib. As part of our target discovery platform, we further validated these screening results using various phenotypic assays. Altogether, our results suggest that resistance to MEK inhibitors is driven by reactivation of the MAPK pathway as previously demonstrated and that impairing such reactivation restores the sensitivity of KRAS mutant cancer cells to trametinib. The genetic mechanisms driving the MAPK pathway rebound are likely different in different cancers and understanding such mechanisms will be key for achieving clinical success. <b>Citation Format:</b> Silvia Fenoglio, Aileen M. Cristo, James Tepper, Teng Teng, Samuel R. Meier, Ashley Choi, Hongxiang Zhang, Shan-chuan Zhao, Shangtao Liu, Leanne G. Ahronian, Daniel Aird, Nikitha M. Das, Yi Yu, Robert Tjin Tham Sjin, Jannik N. Andersen, Alan Huang, Fang Li, Xuewen Pan. CRISPR screens identify sensitizers to trametinib in KRAS mutant cancer cell lines [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P183." @default.
• W4200375449 created "2021-12-31" @default.
• W4200375449 creator A5011106134 @default.
• W4200375449 creator A5029014643 @default.
• W4200375449 creator A5029522150 @default.
• W4200375449 creator A5040096797 @default.
• W4200375449 creator A5044141815 @default.
• W4200375449 creator A5044204104 @default.
• W4200375449 creator A5044530011 @default.
• W4200375449 creator A5047916176 @default.
• W4200375449 creator A5052168116 @default.
• W4200375449 creator A5052640502 @default.
• W4200375449 creator A5060183085 @default.
• W4200375449 creator A5061464835 @default.
• W4200375449 creator A5067918064 @default.
• W4200375449 creator A5070628952 @default.
• W4200375449 creator A5072499098 @default.
• W4200375449 creator A5083656191 @default.
• W4200375449 creator A5085447824 @default.
• W4200375449 creator A5089144108 @default.
• W4200375449 date "2021-12-01" @default.
• W4200375449 modified "2023-10-16" @default.
• W4200375449 title "Abstract P183: CRISPR screens identify sensitizers to trametinib in KRAS mutant cancer cell lines" @default.
• W4200375449 doi "https://doi.org/10.1158/1535-7163.targ-21-p183" @default.
• W4200375449 hasPublicationYear "2021" @default.
• W4200375449 type Work @default.
• W4200375449 citedByCount "0" @default.
• W4200375449 crossrefType "proceedings-article" @default.
• W4200375449 hasAuthorship W4200375449A5011106134 @default.
• W4200375449 hasAuthorship W4200375449A5029014643 @default.
• W4200375449 hasAuthorship W4200375449A5029522150 @default.
• W4200375449 hasAuthorship W4200375449A5040096797 @default.
• W4200375449 hasAuthorship W4200375449A5044141815 @default.
• W4200375449 hasAuthorship W4200375449A5044204104 @default.
• W4200375449 hasAuthorship W4200375449A5044530011 @default.
• W4200375449 hasAuthorship W4200375449A5047916176 @default.
• W4200375449 hasAuthorship W4200375449A5052168116 @default.
• W4200375449 hasAuthorship W4200375449A5052640502 @default.
• W4200375449 hasAuthorship W4200375449A5060183085 @default.
• W4200375449 hasAuthorship W4200375449A5061464835 @default.
• W4200375449 hasAuthorship W4200375449A5067918064 @default.
• W4200375449 hasAuthorship W4200375449A5070628952 @default.
• W4200375449 hasAuthorship W4200375449A5072499098 @default.
• W4200375449 hasAuthorship W4200375449A5083656191 @default.
• W4200375449 hasAuthorship W4200375449A5085447824 @default.
• W4200375449 hasAuthorship W4200375449A5089144108 @default.
• W4200375449 hasConcept C104317684 @default.
• W4200375449 hasConcept C1167327 @default.
• W4200375449 hasConcept C121608353 @default.
• W4200375449 hasConcept C184235292 @default.
• W4200375449 hasConcept C2778472372 @default.
• W4200375449 hasConcept C2781187634 @default.
• W4200375449 hasConcept C2781249067 @default.
• W4200375449 hasConcept C502942594 @default.
• W4200375449 hasConcept C526805850 @default.
• W4200375449 hasConcept C54355233 @default.
• W4200375449 hasConcept C57074206 @default.
• W4200375449 hasConcept C86803240 @default.
• W4200375449 hasConcept C98108389 @default.
• W4200375449 hasConceptScore W4200375449C104317684 @default.
• W4200375449 hasConceptScore W4200375449C1167327 @default.
• W4200375449 hasConceptScore W4200375449C121608353 @default.
• W4200375449 hasConceptScore W4200375449C184235292 @default.
• W4200375449 hasConceptScore W4200375449C2778472372 @default.
• W4200375449 hasConceptScore W4200375449C2781187634 @default.
• W4200375449 hasConceptScore W4200375449C2781249067 @default.
• W4200375449 hasConceptScore W4200375449C502942594 @default.
• W4200375449 hasConceptScore W4200375449C526805850 @default.
• W4200375449 hasConceptScore W4200375449C54355233 @default.
• W4200375449 hasConceptScore W4200375449C57074206 @default.
• W4200375449 hasConceptScore W4200375449C86803240 @default.
• W4200375449 hasConceptScore W4200375449C98108389 @default.
• W4200375449 hasLocation W42003754491 @default.
• W4200375449 hasOpenAccess W4200375449 @default.
• W4200375449 hasPrimaryLocation W42003754491 @default.
• W4200375449 hasRelatedWork W11013498 @default.
• W4200375449 hasRelatedWork W1146978 @default.
• W4200375449 hasRelatedWork W15292524 @default.
• W4200375449 hasRelatedWork W16278512 @default.
• W4200375449 hasRelatedWork W17414462 @default.
• W4200375449 hasRelatedWork W1912601 @default.
• W4200375449 hasRelatedWork W22671550 @default.
• W4200375449 hasRelatedWork W35717447 @default.
• W4200375449 hasRelatedWork W41330241 @default.
• W4200375449 hasRelatedWork W5640370 @default.
• W4200375449 isParatext "false" @default.
• W4200375449 isRetracted "false" @default.
• W4200375449 workType "article" @default.